Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Boule Diagnostics AB's operating assets for the quarter that ended in Mar. 2026 was €41.81 Mil. Boule Diagnostics AB's operating liabilities for the quarter that ended in Mar. 2026 was €6.99 Mil. Boule Diagnostics AB's Total Assets for the quarter that ended in Dec. 2025 was €43.15 Mil. Therefore, Boule Diagnostics AB's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.81.
Boule Diagnostics AB Scaled Net Operating Assets Related Terms
Boule Diagnostics AB Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB Scaled Net Operating Assets Chart
STU:8BD vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.81 mean?
Boule Diagnostics AB (STU:8BD) has a Scaled Net Operating Assets of 0.81 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Scaled Net Operating Assets too high?
Boule Diagnostics AB's current Scaled Net Operating Assets is 0.81. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Scaled Net Operating Assets compare to ABT and SYK?
Boule Diagnostics AB's Scaled Net Operating Assets of 0.81 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Scaled Net Operating Assets is 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (STU:8BD) has a current Scaled Net Operating Assets of 0.81. The stock's GF Value™ is €0.90, compared to a current price of €0.48 — trading 46.7% below its estimated fair value. The current Scaled Net Operating Assets is 0.81. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Boule Diagnostics AB (STU:8BD), the current Scaled Net Operating Assets is 0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (STU:8BD) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of €0.48 is trading 46.7% below its estimated GF Value™ of €0.90.
Key valuation signals for STU:8BD:
Scaled Net Operating Assets: 0.81
GF Value™: €0.90 vs. price of €0.48 (46.7% below fair value)
No single metric tells the full story. See the STU:8BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for STU:8BD
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8BD has been successfully added to your 
